WS #16427
Biogen reported a significant Q3 EPS beat driven by strong revenue growth and raised its full-year outlook, providing a positive signal in the healthcare sector. Conversely, Stellantis reported a $4.5 billion cash drain, highlighting the ongoing challenges in its turnaround plan. In M&A news, LCI Industries confirmed an unsolicited $101/share cash bid from Monomoy, while Otis Worldwide beat estimates, showing resilience in industrial equipment demand.
Corporate Earnings & M&A Activity
Biogen reported a significant Q3 EPS beat driven by strong revenue growth and raised its full-year outlook, providing a positive signal in the healthcare sector. Conversely, Stellantis reported a $4.5 billion cash drain, highlighting the ongoing challenges in its turnaround plan. In M&A news, LCI Industries confirmed an unsolicited $101/share cash bid from Monomoy, while Otis Worldwide beat estimates, showing resilience in industrial equipment demand.